Economic burden and treatment patterns of gynecologic cancers in the United States: evidence from the Medical Expenditure Panel Survey 2007–2014

Abstract

Objective: This study estimated nationally representative medical expenditures of gynecologic cancers, described treatment patterns and assessed key risk factors associated with the economic burden in the United States. Methods: A retrospective repeated measures design was used to estimate the effect of gynecologic cancers on medical expenditures and utilization among women. Data were extracted from the Medical Expenditure Panel Survey (weighted sample of 609,787 US adults) from 2007 to 2014. Using the behavioral model of health services utilization, characteristics of cancer patients were examined and compared among uterine, cervical, and ovarian cancer patients. Multivariable linear regression models were conducted on medical expenditure with a prior logarithmic transformation.

Economic Burden of Gynecological Cancers in Iran

“…This may lead to reduce information bias. Yue et al 30 conducted a study about the economic burden and treatment pattern of GCs based on a panel survey in which patients reported by themselves. They mentioned that some of their information such as survival and stage of disease were missed or had errors because of the use this method.…”

A méhnyakrák okozta éves epidemiológiai és egészségbiztosítási betegségteher Magyarországon

“…A betegségek között a méhtestdaganat volt a legdrágább, ezt követte a petefészek és a méhnyak rosszindulatú daganata. A nőgyógyászati daganatok éves orvosi kiadásainak több mint fele a fekvőbeteg-ellátásnak volt betudható (53%; 2,03 milliárd USD) [39]. Marokkóban a Nemzeti Onkológiai Intézet adatai szerint 2006-ban 550 beteget kezeltek rosszindulatú méhnyakdaganattal, amelynek költsége 1 429 673 USD volt; az átlagot 2599 ± 839 USD-ra becsülték.…”

Temporal trends of healthcare system use between symptomatic presentation and ovarian cancer diagnosis in the United States

“…Even as deaths rates from cancer are falling in the United States (US),1 cancer costs are increasing due to the use of new cancer therapeutics as well as technological advances in imaging, robotics, and radiation therapy 2 3. Although ovarian cancer represents only 2.5% of malignancies among women in the US,4 it has an outsized cost compared with other gynecologic malignancies 3 5. Several factors which seem to drive high overall costs after ovarian cancer diagnosis include inpatient hospitalizations, outpatient services, and drug costs 5–8…”

“…Although ovarian cancer represents only 2.5% of malignancies among women in the US,4 it has an outsized cost compared with other gynecologic malignancies 3 5. Several factors which seem to drive high overall costs after ovarian cancer diagnosis include inpatient hospitalizations, outpatient services, and drug costs 5–8…”